EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access

Candidemia Following Severe COVID ‐19 in Hospitalised and Critical Ill Patients: A Systematic Review and Meta‐Analysis

Karan Srisurapanont iD, Bhoowit Lerttiendamrong iD, Tanaporn Meejun iD, Jaedvara Thanakitcharu iD, Kasama Manothummetha iD, Achitpol Thongkam iD, Nipat Chuleerarux iD, Anawin Sanguankeo iD, Lucy X Li iD, Surachai Leksuwankun iD, Nattapong Langsiri iD, Pattama Torvorapanit iD und 6 weitere

Mycoses · 2024-10 · 67 (10)

DOI: 10.1111/myc.13798 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Mycoses, online erschienen am 08.10.2024. Verfasst von Karan Srisurapanont und 17 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. Hauptthemen laut MEDLINE: Candidemia, COVID-19, Critical Illness, Intensive Care Units. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

The epidemiology and clinical impact of COVID‐19‐associated candidemia (CAC) remained uncertain, leaving gaps in understanding its prevalence, risk factors and outcomes.

Methods

A systematic review and meta‐analysis were conducted by searching PubMed, Embase and Scopus for reports of CAC prevalence, risk factors and clinical outcomes up to June 18, 2024. The generalised linear mixed model was employed to determine the prevalence and 95% confidence intervals (CIs). The risk factors and clinical outcomes were compared between patients with and without CAC using the inverse variance method.

Results

From 81 studies encompassing 29 countries and involving 351,268 patients, the global prevalence of CAC was 4.33% (95% Cl, 3.16%–5.90%) in intensive care unit (ICU) patients. In ICUs, the pooled prevalence of CAC in high‐income countries was significantly higher than that of lower‐middle‐income countries (5.99% [95% Cl, 4.24%–8.40%] vs. 2.23% [95% Cl, 1.06%–4.61%], p = 0.02). Resistant Candida species, including C. auris , C. glabrata ( Nakaseomyces glabratus ) and C. krusei ( Pichia kudriavzveii ), constituted 2% of ICU cases. The mortality rate for CAC was 68.40% (95% Cl, 61.86%–74.28%) among ICU patients. Several risk factors were associated with CAC, including antibiotic use, central venous catheter placement, dialysis, mechanical ventilation, tocilizumab, extracorporeal membrane oxygenation and total parenteral nutrition. Notably, the pooled odds ratio of tocilizumab was 2.59 (95% CI, 1.44–4.65).

Conclusions

The prevalence of CAC is substantial in the ICU setting, particularly in high‐income countries. Several risk factors associated with CAC were identified, including several that are modifiable, offering the opportunity to mitigate the risk of CAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CandidemiaCOVID-19Critical IllnessIntensive Care UnitsHumansAntifungal AgentsCandidaHospitalizationPrevalenceRisk FactorsSARS-CoV-2

Stichwörter der Autor:innen

COVID‐19SARS‐CoV‐2candidemiacandidiasisprevalence

Substanzen

Antifungal Agents

Autor:innen und Institutionen

  • Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Panyananthaphikkhu Cholprathan Medical Center, Srinakharinwirot University, Nonthaburi, Thailand.
  • Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Department of Medicine, University of Miami/Jackson Memorial Hospital, Miami, Florida, USA.

ORCID-Profile: Karan Srisurapanont, Bhoowit Lerttiendamrong, Tanaporn Meejun, Jaedvara Thanakitcharu, Kasama Manothummetha, Achitpol Thongkam, Nipat Chuleerarux, Anawin Sanguankeo, Lucy X Li, Surachai Leksuwankun, Nattapong Langsiri, Pattama Torvorapanit, Navaporn Worasilchai, Rongpong Plongla, Chatphatai Moonla, Saman Nematollahi, Olivia S Kates, Nitipong Permpalung

Förderung

  • NIAID NIH HHS

Zitieren

APA

Srisurapanont, K., Lerttiendamrong, B., Meejun, T., Thanakitcharu, J., Manothummetha, K., Thongkam, A., Chuleerarux, N., Sanguankeo, A., Li, L. X., Leksuwankun, S., Langsiri, N., Torvorapanit, P., Worasilchai, N., Plongla, R., Moonla, C., Nematollahi, S., Kates, O. S., & Permpalung, N. (2024). Candidemia Following Severe COVID ‐19 in Hospitalised and Critical Ill Patients: A Systematic Review and Meta‐Analysis. Mycoses, 67(10). https://doi.org/10.1111/myc.13798

Vancouver

Srisurapanont K, Lerttiendamrong B, Meejun T, Thanakitcharu J, Manothummetha K, Thongkam A, et al. Candidemia Following Severe COVID ‐19 in Hospitalised and Critical Ill Patients: A Systematic Review and Meta‐Analysis. Mycoses. 2024;67(10). doi:10.1111/myc.13798

BibTeX
@article{Srisurapanont2024,
  author = {Srisurapanont, Karan and Lerttiendamrong, Bhoowit and Meejun, Tanaporn and Thanakitcharu, Jaedvara and Manothummetha, Kasama and Thongkam, Achitpol and Chuleerarux, Nipat and Sanguankeo, Anawin and Li, Lucy X and Leksuwankun, Surachai and Langsiri, Nattapong and Torvorapanit, Pattama and Worasilchai, Navaporn and Plongla, Rongpong and Moonla, Chatphatai and Nematollahi, Saman and Kates, Olivia S and Permpalung, Nitipong},
  title = {Candidemia Following Severe COVID ‐19 in Hospitalised and Critical Ill Patients: A Systematic Review and Meta‐Analysis},
  journal = {Mycoses},
  year = {2024},
  volume = {67},
  number = {10},
  doi = {10.1111/myc.13798}
}
Kostenlos starten →